Ascentage Pharma Group International American Depository Shares (AAPG)
NASDAQ: AAPGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AAPG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.12B
- EPS (TTM)
- -$2.26
- Dividend yield
- None
- 52-week range
- 11.97 – 33.09
- Day range
- 11.97 – 12.13
- Volume / Avg
- 5.04K / 6.97K
- Beta
- —
- Shares outstanding
- 93.33M
52-week range
AAPG stock today
Ascentage Pharma Group International American Depository Shares (AAPG) closed at $11.97 on Nov 20, down 3.78% (-$0.47), versus the S&P 500's 3.70% decline. Shares are 63.8% below their 52-week high of $33.09, set on Dec 2, 2025 and 0.0% above the 52-week low of $11.97, near the bottom of the past year's range. AAPG is down 54.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 60.9%.
Ascentage Pharma Group International American Depository Shares has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ascentage Pharma Group International American Depository Shares
Company profileAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Dajun Yang M.D., Ph.D.
- Headquarters
- Suzhou
- Employees
- 828
- IPO year
- 2025
- Website
- ascentage.cn
Financial highlights
Full financialsIn fiscal 2024, Ascentage Pharma Group International American Depository Shares generated $134.3 million in revenue. Ascentage Pharma Group International American Depository Shares reported a net loss of $55.5 million. Gross margin was 97.0%.
| Fiscal year | FY 2024 |
|---|---|
| Revenue | $134.35M |
| Growth | — |
| Net income | $-55.54M |
| EPS (diluted) | $-0.18 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$44.50+271.76%
- Strong buy 3
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
AAPG news
All AAPG news- Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for OlverembatinibGlobeNewswire
- Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026GlobeNewswire
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in LondonGlobeNewswire
- Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLLGlobeNewswire
Ascentage Pharma Group International American Depository Shares peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPSCOMPASS Pathways Plc American Depository Shares | 8.05 | -6.94% | $1.14B | vs AAPG |
| HROWHarrow Inc. | 30.41 | -5.35% | $1.14B | vs AAPG |
| KARDKardigan Inc. | 11.54 | -7.83% | $1.08B | vs AAPG |
| GPCRStructure Therapeutics Inc. ADR | 16.13 | -5.78% | $1.15B | vs AAPG |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs AAPG |
| JBIOJade Biosciences Inc. | 15.31 | +1.66% | $1.06B | vs AAPG |
| NKTRNektar Therapeutics | 30.20 | -7.19% | $1.03B | vs AAPG |
| CTYCity Therapeutics Inc. | 19.32 | +5.29% | $1.03B | vs AAPG |
Indexes, lists and sector
Ascentage Pharma Group International American Depository Shares stock FAQ
What is Ascentage Pharma Group International American Depository Shares's stock price today?
AAPG last traded at $11.97 as of Nov 20, 4:00 PM EST, down 3.78% on the day. Prices are delayed at least 15 minutes.
Who is Ascentage Pharma Group International American Depository Shares's CEO?
Dr. Dajun Yang M.D., Ph.D. is the chief executive officer of Ascentage Pharma Group International American Depository Shares, which has about 828 employees.
What is the AAPG 52-week high?
The 52-week high for AAPG is $33.09 and the 52-week low is $11.97. The stock is currently 63.8% below its high.